Table 1.
Characteristics of the exposure cohort overall and by current use of study medications at the cohort entry date
| Characteristic | Domperidone only | PPI only | Metoclopramide only | Domperidone + PPI | Domperidone + metoclopramide | PPI + metoclopramide | Domperidone + PPI + metoclopramide | Overall |
|---|---|---|---|---|---|---|---|---|
| Sex [N (%)] | ||||||||
| Male | 9285 (30.1) | 269,107 (45.0) | 11,298 (26.6) | 2017 (38.0) | 14 (17.5) | 1661 (38.3) | 10 (43.5) | 293,392 (43.1) |
| Female | 21,580 (69.9) | 328,880 (55.0) | 31,213 (73.4) | 3286 (62.0) | 66 (82.5) | 2674 (61.7) | 13 (56.5) | 387,712 (56.9) |
| Age at cohort entry, years | ||||||||
| Mean (SD) | 44 (23) | 56 (18) | 43 (20) | 51 (22) | 42 (20) | 54 (20) | 51 (20) | 55 (19) |
| Median | 41 | 57 | 39 | 52 | 41 | 54 | 51 | 55 |
| Range | 2–106 | 2–108 | 2–110 | 2–103 | 9–85 | 2–99 | 15–84 | 2–110 |
| Time in baseline period, years | ||||||||
| Mean (SD) | 8.2 (5.2) | 8.1 (5.4) | 7.7 (5.1) | 7.7 (5.6) | 6.8 (5.1) | 7.7 (5.3) | 4.0 (3.8) | 8.1 (5.4) |
| Median | 7.4 | 7.4 | 6.9 | 6.6 | 5.6 | 6.9 | 2.4 | 7.3 |
| Range | 1.0–24 | 1.0–24 | 1.0–24 | 1.0–23 | 1.0–19 | 1.0–23 | 1.0–16 | 1.0–24 |
PPI proton pump inhibitor, SD standard deviation